Journal article
Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative
RJ Edmondson, EJ Crosbie, M Nickkho-Amiry, A Kaufmann, E Stelloo, HW Nijman, A Leary, A Auguste, L Mileshkin, P Pollock, HJ MacKay, ME Powell, T Bosse, CL Creutzberg, HC Kitchener
Gynecologic Oncology | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2017
Abstract
Background The morphological classification of high-risk endometrial cancer is of limited prognostic value. Recent attempts to stratify tumours according to molecular signatures have shown considerable promise. Here we attempted to further refine molecular classifications using markers of the p53 pathway. Methods We analysed the expression of p53 as well as three downstream markers of the p53 pathway, p21, mdm2 and phospho-p63 (pp63), by immunohistochemistry in a series of 114 endometrial cancers (86 endometrioid, 28 non-endometrioid subtype) with high-risk features (such as high tumour grade and deep myometrial invasion) and correlated results with clinical outcome. The Cancer Genome Atlas ..
View full abstractGrants
Awarded by National Institute for Health Research
Funding Acknowledgements
This article represents independent research partly funded by the National Institute for Health Research (NIHR). EJC is funded on an NIHR Clinician Scientist fellowship (NIHR-CS-012-009). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.